BIAFWNCM

bioAffinity Technologies, Inc.

+13.4% · 90d

$0.27

+0.00 (+0.00%)

News

No News Yet

Press releases and SEC filings for BIAFW will appear here as they are published.

Check back later for updates

Key Data

Market Cap—

Open$0.47

Prev Close$0.27

Day Range$0.23 – $0.30

52W Range$0.23 – $0.30

Volume2,052

P/E (TTM)—

EPS—

Dividend Yield—

Beta-0.81

Profit Margin-241.96%

Revenue Growth-27.80%

About

bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.

57 employees

bioaffinitytech.com